Medical Policy Update For April 21, 2022
Reimbursement Policy | Revision |
|---|---|
| Microsatellite Instability and Tumor Mutational Burden Testing AHS-M2178 (PDF) | New policy developed. BCBSNC will provide coverage for 1) tumor mutational (TMB) testing (Note 1) for solid tumors (Note 3) done on tissue or liquid biopsy (Note 2) is considered medically necessary for individuals being considered for Pembrolizumab (Keytruda) therapy and 2) microsatellite instability (MSI) testing (Note 3) by tissue or liquid biopsy (Note 2) for all solid tumors is considered medically necessary for individuals being considered for Pembrolizumab (Keytruda). |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.